IKZF1 deletion is a critical poor prognostic biomarker in ALL (41), the mutation of which drives normal lymphocytes to develop into leukemia (42).It was reported that HSCT could improve clinical outcomes of patients with IKZF1 mutation (43). This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.